



Intercell AG appoints two senior vaccine executives to the Supervisory Board

Vienna (Austria), May 15, 2006 – Intercell AG (VSE, "ICLL") today announced that the following persons have been appointed new members of the supervisory board in the course of Intercell's Annual General Meeting on May 12, 2006 as new members of the supervisory board:

Staph Bakali served as Chief Operating Officer of ID Biomedical. He played a significant role in transforming ID Biomedical from an R&D organization into a fully-integrated biotech company. He was significantly involved in the acquisition of Shire Biologics by ID Biomedical and led the integration efforts. In 2005, ID Biomedical itself was acquired by GlaxoSmithKline. Before his tenure at ID Biomedical, Mr. Bakali has gained significant entrepreneurial experience in building and managing successful companies in the vaccine industry in his previous roles at PowderJect, Chiron and Smithkline Beecham.

Hans Wigzell served as a Chief Scientific Advisor to the Swedish government since 1999, and is also a Professor at the Karolinska Institute in Stockholm and board member of several companies and foundations in Sweden, EU and USA. He spent most of his research career at the Karolinska Institute where he graduated in 1967, becoming Professor of Immunology in 1982 and President of the Karolinska Institute from 1995 to 2003. He is a member of several Swedish and International academies and served as a chairman of the Nobel Committee for Physiology or Medicine from 1990 to 1993.

About Intercell AG

Intercell AG is a biotechnology company focused on the research, development, manufacturing and future commercialization of innovative vaccines for the prevention and treatment of infectious diseases, for which there exists a substantial unaddressed medical need. The Company develops antigens and immunizers (adjuvants), which are derived from its proprietary technology platforms and has in-house GMP manufacturing capability. Intercell has strategic partnerships with a number of global pharmaceutical companies, including sanofi pasteur S.A., Merck & Co., Inc., SciGen Ltd., the Statens Serum Institut and Kirin Brewery Co., Ltd.. The Company has a broad development pipeline with a vaccine product candidate for Japanese Encephalitis in Phase III, a vaccine product candidate for Hepatitis C in Phase II, partnered vaccine candidates for tuberculosis and *S. aureus*, which are in Phase I, and more than five other product candidates focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information, please visit: www.intercell.com





Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communications

Campus Vienna Biocenter 2, A-1030 Vienna

P: +43-1-20620-303

Mail to: kwieser@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.